Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων

We presented a study that showed that NGS-based MRD is
widely
applicable to AML patients, is highly predictive of relapse
and
survival, and may help refine transplantation and
posttransplantation
management in AML patients.
Presenter: Prof. Spyridondis
Patricipants: Dr Liga, Dr Spyridis, Dr Lekka, Dr
Bountouris


We presented Treatments that made headlines in hematology
in 2018. From Nature
Medicine 24,1785–1787 (2018)
Presenter: Prof. Spyridonidis
Paricipants: Dr Liga, Dr Spyridis, Dr Lekka, Dr
Bountouris
Green light
CD19 CAR therapy
Chimeric antigen receptor (CAR) therapy using the CD19 antigen
continued to show its benefits after a long-term follow-up study
found that...


Early-Stage Follicular Lymphoma: What Is the Preferred
Treatment
Strategy in Early-Stage Follicular Lymphoma? WW, RT,
Chemo,
Immunoterpay or a combination of the above? Porobaly lla are
the saem
iof one consideres OS as outocem,but may differ in regard to
EFS.
A critical opinion on a randomized study...


A Japanese study questioned the "favorable" status of AML
with low
allelic ratio FLT3-ITD and NPM1 mutation given by ELN
criteria. Flt3 mut
presence is a clear indication for AML.
Presenter:Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr
Bountouris


Which is the best conditioning in ALL? Slides that we presented
in
EBMT ALWP in Krakow 2018.
The slides present the current policy in Patras.
Presenter: Prof.Spyridonidis
Pariticpants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris


We review again the BK cystitis and our current SOPs. We
discussed the
initiation of a prosepctive study with intravesicular
cidofovir.
Presenter: Prof. Spyridondis
Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr
Bountouris


Retrospective studies indicating that specific
comorbidities are
associated with increased NRM in specific conditoning
regimens. For
example cardiac disease is high toxic in BUFlu
regimens.
These results have been implemented in our daily clinical
praxis.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr
Bountouris.


We presented
the Consensus of North American Experts
regarding MRD in ALL Management and the algorithm for
allo/HSCT.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris.


We discussed the results of a randomized study on
Azacitidine with or
without eltrombopag for first-line treatment of intermediate-
or
high-risk MDS with thrombocytopenia.
The study was closed premature because of a negative effect
of
eltromombag both on thrombocytopenia and time to progress to
AML.
Presenter: Prof. Spyridonidis
Participants: Dr...


The updated results of the Aethera study were presented which
confirmed
the effect of consolidation on PFS.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris.


1. The optimal time
for MRD testing may depend on the type of
MRD. CBFB-MYH11 AML displayed a slower clone
regrowth than AML with the other molecular signatures and
recommended MRD testing for CBFB-MYH11 be performed every
6 months, whereas testing for PML-RARA MRD was
recommended for every 2 months.
2. Another subject of...


We discussed a paper in which the authors measured MRD in AML by
NGS
before allo Tx. They could perfom MRD analysis in most cases and
MRD by
NGS proved the strongest factor for relapse post HCT.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Lekka,...


We updated the current options for the treatment of CNS NHL and
reviewed a
patient series (5 pts) treated with nivolumab for
rrCNS
NHL.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr
Bountouris


The mechanisms of glucocorticoid induced leukocytosis were revealed
during the discussion.
TITLE: A general review of the mechanisms for steroid or
glucocorticoid induced increases in the white blood cell count,
Anthony J Busty, MD, PharmD, FNLA, FAHA.
Link:
https://www.ebmconsult.com/articles/steroids-glucocorticoids-wbc-neutrophiles-increase
Presenter:Dr Bountouris
Participants: Prof. Spyridonidis, Dr Liga, Dr Spyridis,...


The treatment of DCIS T2N0M0 type of breast cancer was discussed
and it was noted that after total mastectomy radiation is not
needed.
Presenter: Dr Bountouris
Participants: Prof. Spyridonidis, Dr Liga, Dr Spyridis, Dr
Lekka.


We discussed the evaluation and differential diagnosis of pineal
tumors in adults, focusing on the pinocytomas.
Presenter: Dr Bountouris.
Participants: Prof.Spyridonidis, Dr Liga, Dr Spyridis, Dr
Lekka.


The excellent review from Zeieser and Blazar on chronic GvHD
published
in NEJM was discussed.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr
Bountouris


We discussed the central role of B cell activation in chronic GVHD
and
discussed the results of ibrutinib in cGVHD which led to FDA
approval.
Presenter: Prof. Spyridonidis
Participants. Dr Liga, Dr Spyridis, Dr Lekka, Dr
Bountouris


The excellent review from Zeieser and Blazar on acute GvHD
published in
NEJM was discussed.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr
Bountouris


